Drugs / Peginterferon Lambda-1a
Peginterferon Lambda-1a
also known as
Pegylated interferon lambda · Lambda · PEG-rIL-29 · BMS-914143 · PEG-interferon lambda · pegIFNλ · PEGylated recombinant interleukin 29
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01708889 | Sep 2012 → Feb 2013 | chronic hepatitis B virus infection, chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00565539 | Dec 2007 → Oct 2009 | chronic hepatitis C virus infection | ZymoGenetics | Completed | No outcome recorded |
| Phase 210 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT04388709 | Sep 2020 → Feb 2021 | COVID-19 | Icahn School of Medicine at Mount Sinai | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04343976 | Jun 2020 → Jul 2021 | COVID-19 | Raymond Chung | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04354259 | May 2020 → Aug 2022 | COVID-19 | University Health Network, Toronto | Completed | Met primary |
| Phase 2 | NCT04331899 | Apr → Aug 2020 | COVID-19 | Stanford University | Completed | Missed primary |
| Phase 2 | NCT04534673 | Apr 2020 → Feb 2023 | COVID-19 | Soroka University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02765802 | Oct 2016 → Jul 2018 | hepatitis D virus infection | EIT Pharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01795911 | Mar 2013 → Apr 2014 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01309932 | Mar 2011 → Jul 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01204762 | Nov 2010 → Dec 2013 | hepatitis B virus infection | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 2 | NCT01001754 | May → Nov 2010 | chronic hepatitis C virus infection | ZymoGenetics | Unknown | No outcome recorded |
| Phase 37 trials · 1 met primary | ||||||
| Phase 3 | NCT05070364 | Dec 2021 → Jun 2024 | hepatitis D virus infection | Eiger BioPharmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT04967430 | Aug 2021 → Mar 2022 | COVID-19 | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 3 | NCT01741545 | Mar 2013 → Jan 2015 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01754974 | Mar 2013 → Sep 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01718158 | Jan 2013 → Oct 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT01598090 | Jun 2012 → Feb 2015 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01447394 | Mar 2012 → Mar 2014 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2012-11-12 | Bristol-Myers Squibb | Results Bristol-Myers Squibb’s Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study bms.com ↗
The SVR12 rate for all genotype 1 infected patients in the Lambda/RBV/DCV group was 76% (28/37). |
| 2012-10-16 | Bristol-Myers Squibb | Results Bristol-Myers Squibb to Present New Data Demonstrating Company’s Continuing Commitment to Research and Development in Liver Disease at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting bms.com ↗
Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to Peginterferon alfa-2a (Alfa) |
| 2012-04-19 | Bristol-Myers Squibb | Results Investigational Compound Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Flu-Like and Musculoskeletal Symptoms in Phase IIb Study in Treatment-Naïve Genotype 2 or 3 Hepatitis C Patients bms.com ↗
In this study, the investigational compound peginterferon lambda-1a (Lambda) plus ribavirin (RBV) achieved sustained virologic response rates 24 weeks post-treatment (SVR 24 ) that were comparable to peginterferon alfa-2a (alfa) plus ribavirin. |
| 2011-04-02 | Bristol-Myers Squibb | Results Investigational Compound PEG-Interferon Lambda Achieved Higher Response Rates with Fewer Flu-Like and Musculoskeletal Symptoms and Cytopenias Than PEG-Interferon Alfa in Phase IIb Study of 526 Treatment-Naive Hepatitis C Patients bms.com ↗ |
| 2011-03-07 | Bristol-Myers Squibb | Results New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011 bms.com ↗
Pegylated Interferon-Lambda (PEGIFN-λ) shows superior viral response with improved safety and tolerability versus PEGIFNα-2A in HCV patients (G1/2/3/4): EMERGE Phase IIb through week 12 (Late-Breakers Oral Session) |
| 2010-10-31 | Bristol-Myers Squibb | Results Bristol-Myers Squibb Posts Data Update on PEG-Interferon Lambda, A Novel Interferon in Development for the Treatment of Hepatitis C bms.com ↗
Bristol-Myers Squibb Company (NYSE: BMY) today posted to the company website an overview of new, 12-week Phase IIa data from the EMERGE study of PEG-Interferon lambda. |
| 2009-10-31 | Bristol-Myers Squibb | Results Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C bms.com ↗
Antiviral activity was observed at all dose levels tested. |
| 2009-04-24 | Bristol-Myers Squibb | Results Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C bms.com ↗
Antiviral activity was observed at all dose levels tested either as single agent or in combination with ribavirin. |
All press releases naming this drug 10 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon Lambda-1a | “BACKGROUND & AIMS: Peginterferon lambda-1a (lambda) is a Type-III interferon, which, like alfa interferons, has antiviral activity in vitro against hepatitis B virus (HBV) and...” PMID 26739688 ↗ Dec 201510“BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2” NCT01708889 ↗ |
| Known as | BMS-914143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01708889 ↗ |
| Known as | Lambda | “BACKGROUND & AIMS: Peginterferon lambda-1a (lambda) is a Type-III interferon, which, like alfa interferons, has antiviral activity in vitro against hepatitis B virus (HBV) and...” PMID 26739688 ↗ Dec 20152“a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis” PMID 33785743 ↗ Mar 2021 “180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection” NCT05070364 ↗ |
| Known as | PEG-interferon lambda | “PEG-rIL-29 (also known as PEG-interferon lambda) is a unique Type III interferon molecule” NCT01001754 ↗ |
| Known as | PEG-rIL-29 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00565539 ↗ |
| Known as | pegIFNλ | “Pegylated Interferon Lambda (pegIFNλ)” NCT01309932 ↗ |
| Known as | Pegylated interferon lambda | “Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7” NCT04534673 ↗ |
| Known as | PEGylated recombinant interleukin 29 | “PEGylated recombinant interleukin 29 (PEG-rIL-29)” NCT00565539 ↗ |
| Modality | Protein / enzyme biologic | “PEGylated recombinant interleukin 29 (PEG-rIL-29)” NCT00565539 ↗ |
| Route | Subcutaneous | “subcutaneous administration either weekly or every other week” NCT00565539 ↗ |